Research & Development
Can monkeypox be asymptomatic?
A Belgian study published in Nature Medicine, which included 224 patient samples, discovered that three of four men with positive monkeypox virus test results reported that they were asymptomatic at the time of testing.
September 1, 2022
BD launches BD COR MX/PX infectious disease platform
BD COR MX/PX integrates and automates the complete molecular laboratory workflow, from sample processing to diagnostic test results, for large, high-throughput labs, the company said.
May 12, 2022
Abbott’s STI test gets FDA nod
The Alinity m STI test uses polymerase chain reaction (PCR) to detect Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium. The test requires one swab sample, or a urine sample collected in a healthcare setting, and it runs on Abbott's Alinity m molecular laboratory instrument.
May 3, 2022
Rheonix gets FDA nod for STI test, workstation
The Encompass MDx workstation enables scalable, multiplexed sample-to-answer detection, simplifying laboratory workflows.
January 11, 2022
BD Cor system features MX instrument for infectious diseases
The new instrument and its first test for sexually transmitted infections have received the CE Mark for IVD directive 98/79/EC.
December 16, 2021
USPSTF: Evidence weak for screening men for chlamydia, gonorrhea
The latest recommendations apply to asymptomatic, sexually active adolescents and adults, including those who are pregnant. The task force concluded with moderate certainty that there was a moderate net benefit to screen for chlamydia and gonorrhea in all sexually active women 24 years or younger and in women 25 years or older who are at increased risk for infection. However, for men it did not issue a screening recommendation.
September 15, 2021
SpeeDx to break ground for new facility
The site will house a range of instrumentation to facilitate clinical trial testing activities in addition to its diagnostic services, the company said.
August 4, 2021
Firm developing rapid gonorrhea test wins $19M prize
Visby Medical won the prize for its patient-side, disposable, molecular polymerase chain reaction (PCR) diagnostic device that detects Neisseria gonorrhoeae as well as markers of drug resistance. The device is a palm-sized, single-use, disposable device that detects N. gonorrhoeae and can determine whether the bacteria is susceptible to a single-dose antibiotic.
August 5, 2020
NeuMoDx launches 4 new CE-IVD tests
The assays work with the company's NeuMoDx 96 and NeuMoDx 288 molecular systems.
June 25, 2019
GlaxoSmithKline recruits SpeeDx for antibiotics trials
SpeeDx markets in vitro testing products internationally that are aimed at minimizing the spread of treatment-resistant infections. Such products include ResistancePlus GC for Neisseria gonorrhoeae bacteria, which recently received the breakthrough device designation from the U.S. Food and Drug Administration (FDA), and ResistancePlus MG for detecting the emerging sexually transmitted infection Mycoplasma genitalium (Mgen). In a statement, the company said that it will use its existing molecular diagnostic tests as well as custom products to assist GlaxoSmithKline in ongoing trials and new product development.
June 23, 2019
FDA clears 1st extragenital STD tests
The tests are designed to detect the presence of the bacteria Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) with extragenital specimens acquired via the throat and rectum. Previously, the tests were cleared only for use with urine, vaginal, and endocervical samples.
May 22, 2019
Page 1 of 1